Friday, July 10, 2026

Drug profile · INN

allopurinol sodium

allopurinol sodium (ALLOPURINOL SODIUM) is a xanthine dehydrogenase inhibitor. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — allopurinol sodium
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

allopurinol sodium (ALLOPURINOL SODIUM) is a xanthine dehydrogenase inhibitor. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN allopurinol sodium
Brand ALLOPURINOL SODIUM
Mechanism Xanthine dehydrogenase inhibitor
Target Xanthine dehydrogenase/oxidase
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Xanthine dehydrogenase inhibitor

Primary target: Xanthine dehydrogenase/oxidase

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. allopurinol Musculo-skeletal system (M04)
  2. febuxostat Musculo-skeletal system (M04)
  3. topiroxostat Xanthine dehydrogenase inhibitor

Frequently asked questions

What is allopurinol sodium?

allopurinol sodium (ALLOPURINOL SODIUM) is a xanthine dehydrogenase inhibitor. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for allopurinol sodium?

ALLOPURINOL SODIUM is a marketed brand name for allopurinol sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of allopurinol sodium?

allopurinol sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.